Irritable Bowel Syndrome Treatment Market size was valued at $ 1,071 million in 2018, and is projected to reach $2,012 million by 2026, growing at a CAGR of 8.2% from 2019 to 2026.
Irritable bowel syndrome is a gastrointestinal tract (GT) illness with the symptoms such as alteration of bowel habits and severe abdominal pain. Usually, the digested food passes through the gastrointestinal tract (GT) and the movement of food is due to intestinal muscle contraction. The irritable bowel syndrome hinders natural movements of that muscle; thus, food material cannot pass through the digestive tract and may result in abdominal pain, diarrhea, mucus in the stool, constipation, bloating & gas, and cramping.
The Centers for Disease Control and Prevention (CDC) suggested that nearly 3 million people in the U.S. were reported being treated with irritable bowel syndrome in 2015. The irritable bowel syndrome can be treated by making changes by proper medication, making changes in daily diet, and reducing stress.
Download PDF Report Sample with statistical info @ https://www.alliedmarketresearch.com/request-sample/6313
The major factors that boost the growth of the global irritable bowel syndrome treatment market are adoption of sedentary lifestyle, rise in level of stress, unhealthy diet, rise in geriatric population, surge in prevalence of gastrointestinal diseases and disorders such as alteration of bowel habit, & abdominal pain, increase in awareness programs for irritable bowel syndrome treatment, and launches of various developed pipeline drugs for the irritable bowel syndrome treatment during the forecast period.
Moreover, increase in prevalence of irritable bowel syndrome in female is expected to further drive the growth of the global irritable bowel treatment market. However, lack of specific treatment which treat all the symptoms of this disorder, and high competition among the key players related to pricing are expected to restrain the irritable bowel syndrome treatment market growth.
Key Findings of the Study:
o Based on type, the IBS with diarrhea (IBS-D) segment held 47.76% share in the global market in 2018.
o Based on product, the rifaximin segment accounted for the largest irritable bowel syndrome treatment market share in 2018 and is expected to remain dominant throughout the forecast period.
o Based on end user, the drug stores & retail pharmacies segment held 54.01% share in the global market in 2018.
o Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 9.9% during the forecast period.
Make an Enquiry for Purchase Report @ https://www.alliedmarketresearch.com/purchase-enquiry/6313
In 2018, North America accounted for the major share in the irritable bowel syndrome market size and is expected to continue this trend, owing to availability of well-developed infrastructure facilities, presence of majority of the key players, rise in gastrointestinal diseases, and huge availability of trained medical professionals.